MediMabBio

MediMabBio is a biotechnology company founded in 2017, with its headquarters in Korea South. The company's slogan emphasizes its focus on developing new therapeutic drugs targeting Oncology and Inflammatory Disease. MediMabBio is dedicated to the generation of novel immunotherapies for the treatment of cancer using advances in systems biology and immunological solutions. The company has developed a pipeline of highly promising drugs and has established collaborations with academic, R&D institutions, and clinical groups in US, UK, Germany, China, and Korea.

The last investment received by MediMabBio was in the form of non-equity assistance at 01 May 2017. The investors in this round were Sunbo Partners and the TIPS Program.

MediMabBio's innovative approach and strategic partnerships position it well in the Biotechnology, Health Care, and Pharmaceutical industries, promising significant advancements in the development of immuno-oncology drugs to address the current limitations of cancer immunotherapy.